solute carrier family 4 member 10Genealiases: NBCn2 · NCBE
Q-omics provides the consensus-scored SLC4A10 profile across patient tissues and cancer cell-line models. SLC4A10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SLC4A10 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SLC4A10 RNA expression shows 14,100 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where SLC4A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC4A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC4A10 survival associations across molecular data types. SLC4A10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC4A10 RNA expression–survival associations across cancer types. High SLC4A10 expression shows unfavorable associations in CESC, UVM and KICH, but favorable associations in BRCA, LIHC and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SLC4A10 RNA expression.
This table summarizes SLC4A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC4A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC4A10 shows lower tumor expression in COAD, LUSC, KICH and READ and higher tumor expression in KIRP and KIRC. The COAD box plot shows higher SLC4A10 RNA expression in normal versus tumor tissue (log2 FC = −1.448, t-test p < 0.001).
This table shows molecular features associated with SLC4A10 in patient tissues and cancer cell lines. In patient samples, SLC4A10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC4A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
